Lung Cancer Clinical Trials in Los Angeles

Showing 61-80 of 283 trials

SP Thoracic IDE Study

NCT05150210

To confirm the safety and performance of the da Vinci SP Surgical System, Instruments and Accessories in pulmonary lobectomy, and in thymectomy procedures.

Primary Lung CancerBenign Lung DiseaseThymoma+1 more

Intuitive Surgical32 participantsStarted Jul 2022

Los Angeles, California, United States • Boston, Massachusetts, United States • New York, New York, United States +3 more locations

ACTIVE_NOT_RECRUITINGPHASE1/PHASE2< 1 mile

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

NCT04198766

This is a Phase 1/2, open-label, non-randomized, 4-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX 106 administered as a single agent or in combination with the anti-PD-1 checkpoint inhibitor (CPI) pembrolizumab (Keytruda®). KEYTRUDA is a registered trademark of Merck Sharp \& Dohme LLC, a subsidiary of Merck \& Co., Inc., Rahway, NJ, USA.

Solid TumorNon-Small Cell Lung CancerHead and Neck Cancer+4 more

Inhibrx Biosciences, Inc296 participantsStarted Dec 2019

Duarte, California, United States • Glendale, California, United States • Los Angeles, California, United States +39 more locations

SP Thoracic IDE Study

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

Lung Cancer Trials in Other Cities

A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy

Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors

Talazoparib and Low-Dose Temozolomide in Treating Participants With Relapsed or Refractory Extensive-Stage Small Cell Lung Cancer

Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors

Utilizing Advocates and Supporters to Increase Lung Cancer Screening Rates in Eligible Participants

Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based Chemotherapy

Oncolytic Adenovirus TILT-123 With Pembrolizumab as Treatment for Refractory Non-Small Cell Lung Cancer

Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors

An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer

Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)

A Phase 1/2 Study of AMG 193 in Combination With IDE397 in Participants With Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors

MAGE A10ᶜ⁷⁹⁶T for Advanced NSCLC

Copper Cu 64 Anti-CEA Monoclonal Antibody M5A PET in Diagnosing Patients With CEA Positive Cancer

Evaluating a Fasting-mimicking Diet in Combination With Immunotherapy in Patients With Non-small Cell Lung Cancer

Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression

A Study of HBI-8000 (Tucidinostat) With Pembrolizumab in Non-Small Cell Lung Cancer

Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung Cancer

A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors (MK-2140-002)

Other Conditions in Los Angeles